Tags

Type your tag names separated by a space and hit enter

Measles control in developing and developed countries: the case for a two-dose policy.
Bull World Health Organ. 1993; 71(1):93-103.BW

Abstract

Despite major reductions in the incidence of measles and its complications, measles control with a single dose of the currently used. Schwarz strain vaccine has failed to eradicate the disease in the developed countries. In developing countries an enormous toll of measles deaths and disability continues, despite considerable efforts and increasing immunization coverage. Empirical evidence from a number of countries suggests that a two-dose measles vaccination programme, by improving individual protection and heard immunity can make a major contribution to measles control and elimination of local circulation of the disease. Cost-benefit analysis also supports the two-dose schedule in terms of savings in health costs, and total costs to society. A two-dose measles vaccination programme is therefore an essential component of preventive health care in developing, as well as developed countries for the 1990s.

Authors+Show Affiliations

Preventive Health Services, Ministry of Health, Jerusalem, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8440043

Citation

Tulchinsky, T H., et al. "Measles Control in Developing and Developed Countries: the Case for a Two-dose Policy." Bulletin of the World Health Organization, vol. 71, no. 1, 1993, pp. 93-103.
Tulchinsky TH, Ginsberg GM, Abed Y, et al. Measles control in developing and developed countries: the case for a two-dose policy. Bull World Health Organ. 1993;71(1):93-103.
Tulchinsky, T. H., Ginsberg, G. M., Abed, Y., Angeles, M. T., Akukwe, C., & Bonn, J. (1993). Measles control in developing and developed countries: the case for a two-dose policy. Bulletin of the World Health Organization, 71(1), 93-103.
Tulchinsky TH, et al. Measles Control in Developing and Developed Countries: the Case for a Two-dose Policy. Bull World Health Organ. 1993;71(1):93-103. PubMed PMID: 8440043.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Measles control in developing and developed countries: the case for a two-dose policy. AU - Tulchinsky,T H, AU - Ginsberg,G M, AU - Abed,Y, AU - Angeles,M T, AU - Akukwe,C, AU - Bonn,J, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez KW - Biology KW - Cost Effectiveness KW - Delivery Of Health Care KW - Developed Countries KW - Developing Countries KW - Diseases KW - Epidemics KW - Evaluation KW - Evaluation Indexes KW - Health KW - Health Services KW - Immunity--changes KW - Immunization KW - Measles KW - Physiology KW - Primary Health Care KW - Quantitative Evaluation KW - Vaccination KW - Viral Diseases SP - 93 EP - 103 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 71 IS - 1 N2 - Despite major reductions in the incidence of measles and its complications, measles control with a single dose of the currently used. Schwarz strain vaccine has failed to eradicate the disease in the developed countries. In developing countries an enormous toll of measles deaths and disability continues, despite considerable efforts and increasing immunization coverage. Empirical evidence from a number of countries suggests that a two-dose measles vaccination programme, by improving individual protection and heard immunity can make a major contribution to measles control and elimination of local circulation of the disease. Cost-benefit analysis also supports the two-dose schedule in terms of savings in health costs, and total costs to society. A two-dose measles vaccination programme is therefore an essential component of preventive health care in developing, as well as developed countries for the 1990s. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/8440043/Measles_control_in_developing_and_developed_countries:_the_case_for_a_two_dose_policy_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/8440043/ DB - PRIME DP - Unbound Medicine ER -